Center Overview

Summary and Overall Plan

These days, it is standard that pharmaceutical companies do not participate directly in basic study of disease, but leave it to academic researches and biological venture businesses. These companies tend to get down to only hopeful compounds which work as drugs at the final phase. In Japan, however, there was no academic organization to comply with the requests about drug discovery.

Our center has been founded in faculty of pharmaceutical sciences as a joint-use center for research and education in order to release academic-made drugs which made in Japan. We do our best to meet the demand from Hokkaido University and external research organization including the companies.

Our center promotes the screening of low molecular weight compounds for the target of intractable disease obtained from basic researches, as one of six core centers of “The Leading-edge Research Infrastructure Program Compound Library Center” supported by the Ministry of Education, Culture, Sports, Science and Technology.

At the same time, we address the development of biomedicine such as antibody preparation and nucleic acid medicine that account for a large amount of primary new medicines. Producing prospective new compounds from both sides of low molecules and macromolecules, we promote the study leading to clinical trial exemptions.

Furthermore, we put great value on education toward young or female researchers along with graduated students so that they will be able to realize their results on the basis of their research for next generation. Our purpose is to become an integrated pharmaceutical facility in Japan.